Derek Dostal
Lawyers
Filters
Rithm Acquisition $230 million SPAC IPO
We advised Rithm Acquisition Corp., a SPAC, on its IPO and NYSE listing
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
Primo Brands $1.4 billion exchange offers and $3.85 billion financings
The transactions included new notes, the refinancing of a $3.1 billion term loan facility and a new $750 million revolving facility
Textron $500 million notes offering
The investment-grade notes are due 2035
Lennar spinoff of Millrose
We advised the financial advisers on the spinoff transaction
Bacardi $1 billion notes offering
The investment-grade notes are due 2030 and 2035
PAR Technology $115 million convertible senior notes offering
The notes are due 2030
Outlook Therapeutics $20.4 million warrant liability transaction
Certain holders agreed to exercise Outlook Therapeutics warrants at a reduced exercise price while receiving new warrants
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
J. M. Smucker cash tender offer
The offer involved five tranches of senior notes